Function in SwissProt
Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:9840937, PubMed:24652652). Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:9840937, PubMed:24652652). One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this activity is inhibited when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492).
Biological Process
Diagram with PDB data |
TP53/EP300 | Structural Basis for the Regulation of p53 Function by p300 |
TP53/CREBBP | NMR Structure of CBP Bromodomain in complex with p53 peptide |
TP53/SETD7 | Crystal structure of a ternary complex of the methyltransferase SET9 (also known as SET7/9) with a P53 peptide and SAH |
TP53/SMYD2 | Structure of SMYD2 in complex with p53 and SAH |
TP53/HMGB1 | HMGB1-facilitated p53 DNA binding occurs via HMG-box/p53 transactivation domain interaction and is regulated by the acidic tail |
TP53/GTF2H1 | Solution structure of the complex between p53 transactivation domain 2 and TFIIH p62 PH domain |
TP53/MDM2 | Crystal Structure of an MDM2/P53 Peptide Complex |
TP53/MDM4 | Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain |
TP53/S100B | SOLUTION STRUCTURE OF THE C-TERMINAL NEGATIVE REGULATORY DOMAIN OF P53 IN A COMPLEX WITH CA2+-BOUND S100B(BB) |
TP53/CCNA2 /CDK2 | CDK2/CyclinA in complex with an 11-residue recruitment peptide from p53 |
TP53/SFN | Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide |
TP53/TP53BP1 | Solution structure of 53BP1 tandem Tudor domains in complex with a p53K382me2 peptide |
See also |
Diagram with PDB data |
MDM4/USP7 | Crystal Structure of the USP7:HdmX(AHSS) complex |
Crebbp/TP53 | Structure of CBP nuclear coactivator binding domain in complex with p53 TAD |
mdm2 | NMR Structure of a Complex Between MDM2 and a Small Molecule Inhibitor |
MDM2/USP7 | The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with mdm2 peptide 147-150 |
mdm4/TP53 | Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain |